These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25411597)

  • 41. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor.
    Tezuka Y; Sekine O; Hirano A; Hanada Y; Nakanishi I; Ariga M; Azuma C; Yamamoto Y; Ito-Kobayashi J; Washiyama M; Iwanishi M; Furuta M; Kanamori M; Shimatsu A; Kashiwagi A
    Diabetes Ther; 2021 Jan; 12(1):431-440. PubMed ID: 33108650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
    Koshizaka M; Ishikawa K; Ishibashi R; Takahashi S; Sakamoto K; Yokoh H; Baba Y; Ide S; Ide K; Ishikawa T; Onishi S; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Maezawa Y; Yokote K
    Diabetes Ther; 2021 Jan; 12(1):183-196. PubMed ID: 33098565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study.
    Yoon JW; Kang SM; Vassy JL; Shin H; Lee YH; Ahn HY; Choi SH; Park KS; Jang HC; Lim S
    J Diabetes Investig; 2012 Jun; 3(3):309-17. PubMed ID: 24843582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy.
    Nagai Y; Fukuda H; Kawanabe S; Nakagawa T; Ohta A; Tanaka Y
    J Clin Med Res; 2019 Apr; 11(4):297-300. PubMed ID: 30937121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan.
    Ishibashi R; Baba Y; Kakinuma K; Takasaki A; Hiraga C; Harama T; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 Jan; 12(1):453-460. PubMed ID: 33237553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes.
    Sugihara H; Nagao M; Harada T; Nakajima Y; Tanimura-Inagaki K; Okajima F; Tamura H; Inazawa T; Otonari T; Kawakami M; Oikawa S
    J Diabetes Investig; 2014 Mar; 5(2):206-12. PubMed ID: 24843762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report.
    Ishizuka T; Tokuyama Y; Horie A; Kanatsuka A
    Diabetol Int; 2021 Jan; 12(1):130-134. PubMed ID: 33479589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study.
    Okada J; Yamada E; Okada K; Okada S; Yamada M
    Curr Ther Res Clin Exp; 2020; 93():100597. PubMed ID: 32874375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma.
    Izumi K; Iimura Y; Hiruma K; Touma T; Tsukamoto T
    IJU Case Rep; 2019 Sep; 2(5):269-271. PubMed ID: 32743434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation.
    Yamada T; Sakaguchi K; Okada Y; Miura H; Otowa-Suematsu N; So A; Komada H; Hirota Y; Ohara T; Kuroki Y; Hara K; Matsuda T; Kishi M; Takeda A; Yokota K; Tamori Y; Ogawa W
    Diabetol Int; 2021 Apr; 12(2):197-206. PubMed ID: 33786274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Oct; 12(10):2801-2805. PubMed ID: 34463953
    [No Abstract]   [Full Text] [Related]  

  • 53. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Jun; 12(6):1765-1768. PubMed ID: 34018149
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
    Terauchi Y; Yokote K; Nakamura I; Sugamori H
    Expert Opin Pharmacother; 2016; 17(4):463-71. PubMed ID: 26800061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):116-25. PubMed ID: 26767080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
    Ohkura T
    World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
    Kutoh E; Wada A; Murayama T; Hirate M
    Drug Res (Stuttg); 2016 Jul; 66(7):345-50. PubMed ID: 27056638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.